Roche Reports Result of Ipatasertib + Tecentriq (atezolizumab) in P-Ib Study for 1L Patients with Advanced Triple-Negative Breast Cancer (TNBC)
Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
Shots:
- The P-Ib study involves assessing of Ipatasertib + Tecentriq + CT (paclitaxel/nab-paclitaxel) in 26 patients with locally advanced or metastatic TNBC
- P-Ib study results: ORR 73%; median duration of follow-up 6.1 mos.; Grade ≥3 AEs 54%; all-grade AEs 88%, Presented at AACR 2019
- Ipatasertib is an oral selective AKT inhibitor targeting three isoforms of AKT further blocking the PI3K/AKT signaling pathway and was developed in collaboration with Genentech & Array BioPharma
Click here to read full press release/ article | Ref: Roche | Image: Chemical Industry Digest